{
    "nct_id": "NCT05417932",
    "official_title": "A Phase 1/ 2a, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma",
    "inclusion_criteria": "* Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)\n* Subjects with HCC who have received at least 2 standard systemic therapies\n* HLA-A *02\n* BCLC stage B or C\n* Child-pugh score ≤ 7\n* Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be 2 × 1000 IU/ml\n* Have at least one measurable leasion at baseline as per mRECIST and RECIST v1.1 criteria\n* Life expectancy of 3 months or greater\n* Ability to provide informed consent form\n* Ability to comply with all the study procedures\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Subjects with history of another primary cancer\n* Untreated or active central nervous system (CNS) or leptomeningeal metastasis, or history of hepatic encephalopathy, or other clinically significant CNS diseases\n* Autoimmune diseases requiring immunosuppressive therapy (except topical medication) or subjects with significant persistent immune rejection\n* Known history of neurological or mental disorder, including epilepsy or dementia\n* Known history of positive results for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS)\n* Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy, CAR T/TCR T cell therapy\n* Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)\n* Any subjects who cannot be evaluated by either triphasic liver CT or triphasic MRI because of allergy or other contraindication to both CT and MRI contrast agents\n* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation",
    "miscellaneous_criteria": "Main"
}